Interferon gamma-1b as Therapy for Idiopathic Pulmonary Fibrosis: An Intrapatient Analysis

Respiration

Volumn 71, Issue 1, 2004, Pages 77-82

  Nathan, Steven D ^a   Barnett, Scott D ^b   Moran, Brian ^a   Helman, Donald L ^c   Nicholson, Karin ^c   Ahmad, Shahzad ^a   Shorr, Andrew F ^c  

^a INOVA FAIRFAX HOSPITAL   (United States)

^b INOVA FAIRFAX HOSPITAL   (United States)

^c WALTER REED ARMY MEDICAL CENTER   (United States)

Author keywords

Interferon gamma, recombinant; Lung transplantation; Pulmonary fibrosis; Respiratory function tests

Indexed keywords

CARBON DIOXIDE; GAMMA1B INTERFERON; PREDNISONE;

ADULT; AGED; ARTICLE; BREATHING; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE COURSE; FEMALE; FORCED EXPIRATORY VOLUME; HUMAN; LUNG FIBROSIS; LUNG FUNCTION TEST; MALE; PRIORITY JOURNAL; REGRESSION ANALYSIS; REMISSION; TREATMENT OUTCOME;

COHORT STUDIES; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; FOLLOW-UP STUDIES; HOSPITALIZATION; HUMANS; INJECTIONS, SUBCUTANEOUS; INTERFERON-GAMMA, RECOMBINANT; MALE; PROBABILITY; PULMONARY FIBROSIS; RESPIRATORY FUNCTION TESTS; RETROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX; STATISTICS, NONPARAMETRIC; TREATMENT OUTCOME;

EID: 1242351642     PISSN: 00257931     EISSN: None     Source Type: Journal    
DOI: 10.1159/000075653     Document Type: Article

References (14)

1. Katzenstein A, Myers J: Idiopathic pulmonary fibrosis: Clinical relevance of pathologic classification. Am J Respir Crit Care Med 1998;157:1301-1315.
2. Selman M, King T, Pardo A: Idiopathic pulmonary fibrosis: Prevailing and evolving hypotheses about its pathogenesis and implications for therapy. Ann Intern Med 2001;134:136-151.
3. Shorr AF, Davies D, Nathan SD: Outcomes for patients with sarcoidosis awaiting lung transplantation. Chest 2002;122:233-238.
4. Gross TJ, Hunninghake GW: Idiopathic pulmonary fibrosis. N Engl J Med 2001;345:517-525.
5. Strieter RM: Mechanisms of pulmonary fibrosis. Chest 2001;120:77S-85S.
6. Ziesche R, Hofbauer E, Wittmann K, Petkov V, Block L: A preliminary study of long-term treatment with interferon gamma-1b and lowdose prednisolone in patients with idiopathic pulmonary fibrosis. N Engl J Med 1999;341:1264-1269.
7. Hanson D, Winterbauer RH, Kirtland SH, Wu R: Changes in pulmonary function test results after 1 year of therapy as predictors of survival in patients with idiopathic pulmonary fibrosis. Chest 1995;108:305-310.
8. Official Statement of the American Thoracic Society: Lung function testing: Selection of reference values and interpretative strategies. Am Rev Respir Dis 1991;144:1202-1218.
9. Idiopathic pulmonary fibrosis: Diagnosis and treatment. International consensus statement. Am J Respir Crit Care Med 2000;161:646-664.
10. Ross DJ, Lewis MI, Kramer M, Vo A, Kass RM: FK 506 'rescue' immunosuppression after lung transplantation. Chest 1997;112:1175-1179.
11. Revell MP, Lewis ME, Llewellyn CG, Wilson IC, Bonser RS: Conservation of small-airway function by tacrolimus/cyclosporine conversion in the management of bronchiolitis obliterans following lung transplantation. J Heart Lung Transplant 2000;19:1219-1223.
12. Honoer I, Nunes H, Groussard O, Kamboucher M, Chambellan A, et al: Acute respiratory failure after interferon therapy of end-stage pulmonary fibrosis. Am J Resp Crit Care Med 2003;167:953-957.
13. Guyatt GH, Sackett D, Taylor DW, et al: Determining optimal therapy-randomized trials in individual patients. N Engl J Med 1986;34:889-895.
14. Official Statement of the American Thoracic Society: Single-breath carbon monoxide diffusing capacity (transfer factor). Am J Respir Crit Care Med 1995;152:2185-2198.